FelipeSamaniegoMD

Oncology • Houston, TX

Professor, Oncology, University of Texas MD Anderson Cancer Center

Join to view full profile

Dr. Samaniego is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Samaniego's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 832-729-0759

Fax+1 713-792-7543

Summary

Dr. Felipe Samaniego is an oncologist in Houston, TX and is affiliated with University of Texas M.D. Anderson Cancer Center. He received his medical degree from Harvard Medical School and has been in practice for 34 years. He speaks multiple languages, including Spanish. Dr. Samaniego specializes in hematologic oncology and is experienced in hematopoietic stem cell transplantation, follicular lymphoma, health outcomes research, general medical oncology, and gout suppressants.

Meet lymphoma oncologist Felipe Samaniego, M.D.

Felipe Samaniego, M.D.; Professor-Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center Website: https://faculty.mdanderson.org/profiles

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1986 - 1990
University of ColoradoResidency, Internal Medicine, 1983 - 1986
Harvard Medical SchoolClass of 1983

Certifications & Licensure

AZ State Medical License 2022 - 2026
NM State Medical License 2023 - 2026
TN State Medical License 2022 - 2025
WA State Medical License 2022 - 2025
GA State Medical License 2022 - 2024
LA State Medical License 2022 - 2024
MS State Medical License 2022 - 2024
TX State Medical License 2011 - 2024
AL State Medical License 2023 - 2023
MD State Medical License 1995 - 2001
CO State Medical License 1985 - 1991
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

Waun Ki Hong Award for Excellence in Team Science The University of Texas MD Anderson Cancer Center, 2016
ASH Annual Meeting, Moderator American Society of Hematology, 2016
Robert Wood Johnson Foundation Fellow 1989-2016
Regional Top Doctor 2014
US News and World Report Top Docs 2012-2013
AACR-MICR Council Member AACR-MICR, 2002
Daland Fellowship, Alternate Fellow 1989
Join now to see all

Clinical Trials

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas Start of enrollment: 2015 Jul 01
Active, not recruiting
Phase 1, Phase 2
Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) Start of enrollment: 2016 May 23
Active, not recruiting
Phase 3
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma Start of enrollment: 2016 May 25
Terminated
Phase 2, Phase 3
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma Start of enrollment: 2016 Oct 01
Terminated
Phase 1
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma Start of enrollment: 2017 Jan 01
Active, not recruiting
Phase 3
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas Start of enrollment: 2019 Apr 30
Active, not recruiting
Phase 1
A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2019 Apr 03
Active, not recruiting
Phase 1
Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2019 Sep 13
Completed
Phase 2
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas Start of enrollment: 2020 Mar 24
Terminated
Phase 1, Phase 2
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia Start of enrollment: 2021 Apr 23
Active, not recruiting
Phase 1
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Start of enrollment: 2015 Jul 01
Withdrawn
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) Start of enrollment: 2022 Jan 14
Recruiting
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

3 citations
Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial.
Jillian R Gunther, Jie Xu, Manoop S Bhutani, Paolo Strati, Penny Q Fang
The Lancet. Haematology. 2024-07-01
Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 s...
Max J Gordon, Lei Feng, Paolo Strati, Hun Ju Lee, Fredrick B Hagemeister
Cancer. 2024-03-15
20 citations
Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma.
Jason Westin, R Eric Davis, Lei Feng, Fredrick Hagemeister, Raphael Steiner
Journal of Clinical Oncology. 2023-02-01

Journal Articles

Long‐Term Overall‐ and Progression‐Free Survival After Pentostatin, Cyclophosphamide and Rituximab Therapy for Indolent Non‐Hodgkin Lymphoma
Peter McLaughlin, M Alma Rodriguez, Sattva S Neelapu, Anas Younes, Lei Feng, Michelle A Fanale, Felipe Samaniego, Barbara Pro, Luis Fayad, Fredrick Hagemeister, Jorge ..., British Journal of Haematology
Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study
Felipe Samaniego, Boris Blechacz, Ahmed Kaseb, Bruno P Granwehr, Aung Naing, Issam I Raad, Ethan Miller, Harrys A Torres, Nature
Resolution of lung adenocarcinoma after discontinuation of ibrutinib
Khashab T, Loghavi S, Konoplev SN, Samaniego F, BMJ Case Rep, 2016

Abstracts/Posters

Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma
Hamadani ME, Collins GP, Phil D, Samaniego F, Spira AI, Davis AN, Radford J, Caimi P, Menne TO, Boni J, Cruz H, Feingold J, He SH, Wuerthner J, Horwitz SM, Blood, 12/2018
Acalabrutinib plus pembrolizumab in relapsed/refractory diffuse large b‐cell lymphoma: a phase 1/2 study
Witzig TE, Maddocks K, Vos S, Lyons R, Edenfield W, Sharman J, Yimer H, Wei H, Chan E, Patel P, Simone C, Gandhi M, Vaughn J, Kolibaba K, Cheson B, Samaniego F, Hematological Oncology, 6/2019
Preliminary results of astx660, a novel non‐peptidomimetic ciap1/2 and xiap antagonist, in relapsed/refractory peripheral t‐cell lymphoma and cutaneous t cell lymphoma
Samaniego F, Hollebecque A, Foss F, Lister J, Mita M, Wagner-Johnston N, Dyer M, You B, Prica A, Hernandez-Llizaliturri F, Ferraldeschi R, Chan D, Zhang J, Mehta A, Hematological Oncology, 6/2019
Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: a multicenter, open‐label, registration directed p...
Zinzani P, Samaniego F, Jurczak W, Lech-Maranda E, Ghosh N, Anz B, Patten P, Reeves J, Leslie LA, Smolewski P, Chavez JC, Scarfo L, Derenzini E, Burke JM, Sharman J, K..., Hematological Oncology, 6/2019
A Phase I/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent Lymphoma
Nathan H Fowler, Loretta J. Nastoupil, Collin Chin, Paolo Strati, Fredrick B. Hagemeister, Luis E. Fayad, Jason R. Westin, Sheryl G Forbes, Janine Arafat, Lei Feng, Ra..., Blood, 11/2019
Analysis of clinical determinants driving safety and efficacy of camidanlumab tesirine (adct‐301, cami) in relapsed/refractory (r/r) classical hodgkin lymphoma (chl)
Collins G, Horwitz S, Hamadani M, Samaniego F, Spira A, Caimi P, Davies A, Menne T, Fields P, Cruz H, He S, Boni J, Feingold J, Wuerthner J, Radford J, Hematological Oncology, 6/2019
Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma
Paolo Strati, MD , Sudhakar Tummala , Loretta J. Nastoupil, MD MSc , Jason R. Westin, MD , Luis Fayad, MD , Sairah Ahmed, MD , Nathan H. Fowler, MD , F. B. Hagemeister..., Blood, 11/2019
High response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: interim results of an on open‐label, phase ii study
Nastoupil LJ, Westin J, Fowler N, Fanale M, Samaniego F, Oki Y, Obi C, Cao J, Cheng X, Ma M, Wang Z, Chu F, Feng L, Zhou S, Davis S, Neelapu SS, Hematological Oncology, 6/2019
Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Re...
Loretta J. Nastoupil, MD MSc , Sattva S Neelapu, MD , Eric Davis, MD , Felipe Samaniego, MD , Nathan H Fowler, MD , Jason R. Westin, MD , Hun Ju Lee , Michael Wang, MD..., Blood, 11/2019
Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age _ 65 years) with Mantle C...
Felipe Samaniego, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)
Felipe Samaniego, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Comparative Review of 30 Day Non-Relapse Mortality (NRM) in B-Cell Lymphomas Associated with Anti-CD19 Chimeric Antigen Receptor T-Cells (CAR-T) from FDA Database, Cli...
Felipe Samaniego, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase I/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent Lymphoma
Felipe Samaniego, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age _ 65 years) with Mantle C...
Felipe Samaniego, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell LymphomaRadiation Therapy Can be ...
Felipe Samaniego, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Clinical Relevance of MYC/BCL2 and Cell of Origin in Patients with Relapsed Diffuse Large B-Cell Lymphoma Treated with Autologous Stem Cell Transplantation
Felipe Samaniego, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110_/_ Inhibitor in Patients with Relapsed/Re...
Felipe Samaniego, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma
Felipe Samaniego, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or...
Felipe Samaniego, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Predictive Factors of Response and Survival of Lenalidomide and Rituximab As Initial Treatment of Follicular Lymphoma
Felipe Samaniego, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Nonmyeloablative Allogeneic Transplantation (NMAT) Confers an Overall Survival Benefit with Similar Non-Relapse Mortality When Compared to Autologous Stem Transplantat...
Felipe Samaniego, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Prognostic Factors, Outcomes and Clinical Characteristics in Patients with Transformed Follicular Lymphoma (t-FL): Cohort Study of Patients
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Seven Year Follow up and Comparison of Dosing Strategies from the Pivotal Phase II Clinical Trial of Lenalidomide Plus Rituximab (R) in Previously Untreated Follicular...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid LeukemiaDecember 13th, 2021
Early Experience with Remdesivir to Treat Severe COVID-19 PublishedApril 10th, 2020
Best of MD Anderson 2019: Top Cancer Insights from Our ExpertsDecember 17th, 2019
Join now to see all

Grant Support

Randomized, Open-label, Phase 3 Trial of Nivolumab plus Brentuximab vedotin versus Brentuximab vedotin alone in Participants with Relapsed Refractory or Ineligible for Autologous Stem Cell TransplantBristol-Myers Squibb2017–2021
A Phase III, Randomized, Open-Label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin LymphomaMerck Sharp & Dohme Corp2016–2020
Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and LymphomasAstex Pharmaceuticals2017–2019
A Phase 1b/2 Proof-of-Concept Study of the Combination of ACP-196 and Pembrolizumab in Subjects with B-cell MalignanciesAcerta Pharma LLC2016–2019
Study of a PI3K inhibitor in ibrutinib resistant diffuse large B cell lymphomaKarus Therapeutics2016–2018
Cancer Cell Overexpression of Death Receptor ModularNIH/NCI2012–2014
Preservation of liver function through modulation of Fas-binding proteinsNIH2011–2014
Specialized Program of Research ExcellenceNIH2011–2013
Gastrointestinal Research Regulation of Proliferation and Apoptosis in Hepatocellular CarcinomaHogan2011–2013
Gastrointestinal Research Regulation of Proliferation and Apoptosis in Hepatocellular CarcinomaG.S. Hogan2011–2013
PMLRARa and PML directly regulate Fas-mediated apoptosis in vivoNIH2011–2013
Targeting of Fas Inhibitor Proteins in Hematopoietic CancersLeukemia and Lymphoma Society2008–2011
Correlative studies in treatment of CLL with MilatuzimabLadies Leukemia League2009–2010
Targeting CD74 in the therapy of lymphomaCancer Fighters Houston2009–2010
Fas Inhibitors in Hematopoietic CancersUTMDACC Center for Targeted Therapy (CTT)2008–2010
Analysis of Fas-inhibitor regulation of apoptosis in normal and malignant tissuesU. T. M.D. Anderson Cancer Center2008–2010
K1 from HHV-8 Modulates Fas: A Model for Inducing Cell SuicideLeukemia and Lymphoma Society2005–2010
Human herpesvirus 8 K1 as a model for regulation of apoptosisHogg Foundation2007
HHV-8 K1 Lymphoid Hyperplasia and Suppressed ApoptosisMD Anderson Cancer Center2006–2007
HIV-1 Tat Activates PKB/Akt and Enhances Cell SurvivalNIH/ NCI2004–2006
Lymphocytes Expressing Human Herpes Virus 8 K1 Show NF-kB ActivationConcern Foundation2002–2004
Tat's Promotion of Kaposi's SarcomaNIH/ NCI1999–2004